Market Access
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Roche Seen Offering NICE Further Price Cut For MS Drug Ocrevus
UK HTA provisionally tells Roche price for supplying MS blockbuster Ocrevus to the NHS not good enough – 'try again'.
Market Access
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Market Access
Rigel Readies Tavalisse For Late-May Launch After FDA Approval
Rigel has its first US FDA approval for Tavalisse (fostamatinib) and plans to launch the drug for adults with immune thrombocytopenia (ITP) in late May, after working on the drug's development for more than a decade across multiple indications.
Call For India Compulsory Licenses For Last Resort TB Drugs
Public health campaigners in India and globally are pushing the government to allow Indian generic firms to make cheap copies of two new-generation, last resort antibiotics for drug-resistant tuberculosis through the use of patent-busting compulsory licenses.
Amazon And The Case For Major Health Care Disruption
From drug delivery by drone to busting the drug rebate model, panelists at CNBC's inaugural health care conference had big visions for the changes Amazon could bring to health care.
J&J Stays Within Price Pledge, But Average Doesn't Tell The Whole Story, Analyst Says
Drug Pricing: A Game Of Chutes & Ladders
The US drug pricing policy environment is facing changes. Much of the action, whether Congressional or regulatory, is good for industry – but there have been a few setbacks and more may come.
The Ups and Downs Of US Drug Pricing Policy
If 2017 was the year of talk (tweets) on prescription drug pricing policy, 2018 is shaping up to be the year of action.
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.